The Manufacturers Life Insurance Company Boosts Holdings in Tango Therapeutics, Inc. $TNGX

The Manufacturers Life Insurance Company increased its position in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 234.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,218 shares of the company’s stock after purchasing an additional 75,876 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.08% of Tango Therapeutics worth $2,264,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc increased its stake in Tango Therapeutics by 30.7% during the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after purchasing an additional 1,640 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Tango Therapeutics by 26.7% during the fourth quarter. Russell Investments Group Ltd. now owns 9,794 shares of the company’s stock valued at $87,000 after acquiring an additional 2,065 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Tango Therapeutics by 52.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock valued at $58,000 after acquiring an additional 2,243 shares in the last quarter. SG Americas Securities LLC raised its holdings in Tango Therapeutics by 10.2% in the 1st quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock worth $507,000 after acquiring an additional 2,251 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Tango Therapeutics by 0.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 489,348 shares of the company’s stock worth $10,237,000 after acquiring an additional 2,272 shares during the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Price Performance

NASDAQ TNGX opened at $27.07 on Friday. The business’s fifty day moving average price is $28.47 and its 200-day moving average price is $21.76. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of -32.61 and a beta of 1.16. Tango Therapeutics, Inc. has a 1-year low of $6.25 and a 1-year high of $34.39.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, hitting the consensus estimate of ($0.32). Equities research analysts anticipate that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on TNGX. Mizuho increased their target price on Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. HC Wainwright boosted their price target on Tango Therapeutics from $27.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Piper Sandler cut Tango Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $16.00 to $24.00 in a research report on Thursday, May 14th. Weiss Ratings lowered Tango Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. Finally, Stifel Nicolaus raised their price target on shares of Tango Therapeutics from $24.00 to $40.00 and gave the company a “buy” rating in a report on Monday, April 27th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.15.

Insider Transactions at Tango Therapeutics

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total transaction of $798,930.00. Following the completion of the sale, the insider directly owned 115,743 shares in the company, valued at $3,424,835.37. The trade was a 18.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 6.50% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.